Efficacy and Safety of Eplivanserin 5mg/Day on Sleep Maintenance Insomnia: a 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
Phase of Trial: Phase III
Latest Information Update: 04 Mar 2016
At a glance
- Drugs Eplivanserin (Primary)
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Acronyms GEMS
- Sponsors Sanofi
- 09 Jun 2009 Actual patient number (967) added as reported by ClinicalTrials.gov.
- 13 Mar 2008 Status changed from in progress to completedas reported by ClinicalTrials.gov
- 15 Nov 2007 Eplivanserin is expected to be launched in 2009.